2. PI3K/Akt/mTOR Autophagy Apoptosis
  3. PI3K Akt mTOR Autophagy Apoptosis
  4. Veratramine

Veratramine  (Synonyms: NSC17821; NSC23880)

Cat. No.: HY-N0837 Purity: 99.84%
COA
SDS
Handling Instructions Technical Support

Veratramine (NSC17821; NSC23880) is an orally active inhibitor of the PI3K/Akt/mTOR signaling pathway and a SIGMAR1 modulator. Veratramine induces autophagic apoptosis of tumor cells, arrests the cell cycle at the G0/G1 phase, and inhibits epithelial-mesenchymal transition (EMT)-related proteins to reduce tumor migration. Veratramine reduces spinal cord and sciatic nerve pathological damage in a neuropathy model by inhibiting SIGMAR1 binding to NMDAR and phosphorylation of NMDAR Ser896. Veratramine has anti-tumor proliferation, apoptosis induction, anti-inflammatory and neuroprotective activities, and can be used in the study of cancers such as liver cancer and osteosarcoma, as well as diabetic peripheral neuropathy.

For research use only. We do not sell to patients.

CAS No. : 60-70-8

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg In-stock
100 mg In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Veratramine:

Veratramine Related Antibodies

Top Publications Citing Use of Products

1 Publications Citing Use of MCE Veratramine

IHC
WB
RT-PCR
Histological Imaging/Staining

    Veratramine purchased from MedChemExpress. Usage Cited in: Pharm Biol. 2022 Dec;60(1):2145-2154.  [Abstract]

    Immunohistochemistry (IHC) was used to stain and localise SIGMAR1 protein in rat spinal cord tissue treated with Veratramine (50 μg/kg, tail vein).

    Veratramine purchased from MedChemExpress. Usage Cited in: Pharm Biol. 2022 Dec;60(1):2145-2154.  [Abstract]

    WB was used to detect the protein expression level of SIGMAR1 treated with Veratramine (50 μg/kg, tail vein).

    Veratramine purchased from MedChemExpress. Usage Cited in: Pharm Biol. 2022 Dec;60(1):2145-2154.  [Abstract]

    The spinal cord tissues of rats in each group were examined for SIGMAR1 gene expression leves by qPCR treated with Veratramine (50 μg/kg, tail vein).

    Veratramine purchased from MedChemExpress. Usage Cited in: Pharm Biol. 2022 Dec;60(1):2145-2154.  [Abstract]

    H&E photomicrographs of spinal cord tissue treated with Veratramine (50 μg/kg, tail vein).

    View All PI3K Isoform Specific Products:

    View All Isoforms
    PI3Kα PI3Kβ PI3Kγ PI3Kδ PI3KC2α PI3KC2β PI3KC2γ Vps34 PI3K PI3KC3 p120γ

    View All Akt Isoform Specific Products:

    View All Isoforms
    Akt Akt1 Akt2 Akt3

    View All mTOR Isoform Specific Products:

    View All Isoforms
    mTOR mTORC1 mTORC2

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Veratramine (NSC17821; NSC23880) is an orally active inhibitor of the PI3K/Akt/mTOR signaling pathway and a SIGMAR1 modulator. Veratramine induces autophagic apoptosis of tumor cells, arrests the cell cycle at the G0/G1 phase, and inhibits epithelial-mesenchymal transition (EMT)-related proteins to reduce tumor migration. Veratramine reduces spinal cord and sciatic nerve pathological damage in a neuropathy model by inhibiting SIGMAR1 binding to NMDAR and phosphorylation of NMDAR Ser896. Veratramine has anti-tumor proliferation, apoptosis induction, anti-inflammatory and neuroprotective activities, and can be used in the study of cancers such as liver cancer and osteosarcoma, as well as diabetic peripheral neuropathy[1][2][3][4].

    In Vitro

    Veratramine (2.5-80 μM; 24-72 h) inhibits cell proliferation, migration and invasion, induces G0/G1 arrest and autophagic apoptosis, and downregulates proteins related to the PI3K/Akt/mTOR signaling pathway in human hepatoma HepG2 cell experiments[1].
    Veratramine (30-50 μM; 24-48 h) inhibits cell viability, migration and invasion, induces apoptosis, and downregulates p-PI3K, p-Akt, and EMT-related proteins N-cadherin and vimentin in human osteosarcoma 143B and HOS cell experiments[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Veratramine Related Antibodies

    Cell Cycle Analysis[1]

    Cell Line: HepG2 liver cancer cells
    Concentration: 10, 20, 40 μM
    Incubation Time: 48 h
    Result: Flow cytometry revealed a dose-dependent increase in apoptotic cells (Annexin V+), with the highest apoptosis rate (51.86%) at 40 μM.
    Cell cycle analysis showed G0/G1 phase arrest, with a significant reduction in S phase cells at 40 μM.

    Western Blot Analysis[1]

    Cell Line: HepG2 liver cancer cells
    Concentration: 0, 10, 20, 40 μM
    Incubation Time: 48 h
    Result: Downregulated p-PI3K, p-Akt, and p-mTOR, and upregulated autophagy markers Beclin-1 and LC3-II/I.
    Pro-apoptotic protein Bax was increased, while anti-apoptotic Bcl-2 was decreased.

    Cell Migration Assay [2]

    Cell Line: 143B and HOS osteosarcoma cells
    Concentration: 0, 30, 40, 50 μM
    Incubation Time: 24-48 h
    Result: Wound healing and Transwell assays showed reduced migration and invasion at 40 μM and 50 μM.

    Western Blot Analysis[2]

    Cell Line: 143B and HOS osteosarcoma cells
    Concentration: 0, 30, 40, 50 μM
    Incubation Time: 24-48 h
    Result: Western blot revealed decreased N-cadherin, Snail, vimentin, and MMP-2, indicating inhibition of epithelial-mesenchymal transition (EMT).
    In Vivo

    Veratramine (2 mg/kg; tail vein injection; 3 times a week; 4 weeks) inhibits tumor growth and reduces tumor weight in the subcutaneous transplant model of liver cancer in BALB/c nude mice, without obvious systemic toxicity[1].
    Veratramine (50 μg/kg; tail vein injection; once a day; 4 weeks) increases the mechanical pain threshold in the diabetic peripheral neuropathy model of Sprague-Dawley rats, prolongs the tolerance time to cold and hot stimuli, and reduces the pathological damage of the spinal cord and sciatic nerve[3].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: BALB/c Nude Mouse Hepatocellular Carcinoma Model (female, 16-18 g, 4-6 weeks old): subcutaneous hepatocellular carcinoma xenografts (HepG2 cells)[1]
    Dosage: 2 mg/kg
    Administration: Tail vein injection, 3 times a week for 4 weeks
    Result: Significantly decreased the tumor volume was smaller compared to the control group. Reduced the average tumor weight.
    There were no significant differences in body weight, food intake, or water intake between the two groups.
    Led to a decrease in the number of proliferating cells and an increase in apoptotic cells in the tumor tissue in Histopathological examination.
    Animal Model: Sprague-Dawley Rat Diabetic Peripheral Neuropathy Model (male, 260-300 g, 8 weeks old): Streptozotocin-induced diabetic peripheral neuropathy[3]
    Dosage: 50 µg/kg
    Administration: Tail vein injection, once a day for 4 weeks
    Result: Significantly increased he mechanical pain threshold and cold/hot stimulus tolerance time compared to the diabetic control group.
    Resulted the spinal cord and sciatic nerve less damage in Histological examination.
    Downregulated the expression of p-mTOR and p-4E-BP1 in the spinal cord and sciatic nerve tissues.
    Molecular Weight

    409.60

    Formula

    C27H39NO2
    CAS No.
    Appearance

    Solid

    Color

    White to off-white

    SMILES

    O[C@H]1[C@H]([C@H](C2=C(C)C3=C(C=C2)[C@]4([H])CC=C(C[C@@H](O)CC5)[C@@]5(C)[C@@]4([H])C3)C)NC[C@@H](C)C1
    Structure Classification
    Initial Source
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 2 years
    -20°C 1 year
    Solvent & Solubility
    In Vitro: 

    DMSO : ≥ 100 mg/mL (244.14 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    *"≥" means soluble, but saturation unknown.

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 2.4414 mL 12.2070 mL 24.4141 mL
    5 mM 0.4883 mL 2.4414 mL 4.8828 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.5 mg/mL (6.10 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.5 mg/mL (6.10 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation

    Purity: 99.84%

    SDS (396 KB)

    COA (250 KB) LCMS (86 KB)

    Handling Instructions (2659 KB)
    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 2.4414 mL 12.2070 mL 24.4141 mL 61.0352 mL
    5 mM 0.4883 mL 2.4414 mL 4.8828 mL 12.2070 mL
    10 mM 0.2441 mL 1.2207 mL 2.4414 mL 6.1035 mL
    15 mM 0.1628 mL 0.8138 mL 1.6276 mL 4.0690 mL
    20 mM 0.1221 mL 0.6104 mL 1.2207 mL 3.0518 mL
    25 mM 0.0977 mL 0.4883 mL 0.9766 mL 2.4414 mL
    30 mM 0.0814 mL 0.4069 mL 0.8138 mL 2.0345 mL
    40 mM 0.0610 mL 0.3052 mL 0.6104 mL 1.5259 mL
    50 mM 0.0488 mL 0.2441 mL 0.4883 mL 1.2207 mL
    60 mM 0.0407 mL 0.2035 mL 0.4069 mL 1.0173 mL
    80 mM 0.0305 mL 0.1526 mL 0.3052 mL 0.7629 mL
    100 mM 0.0244 mL 0.1221 mL 0.2441 mL 0.6104 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Veratramine Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Veratramine60-70-8NSC17821 NSC23880NSC 17821NSC-17821NSC23880NSC 23880NSC-23880PI3KAktmTORAutophagyApoptosisPhosphoinositide 3-kinasePKBProtein kinase BMammalian target of RapamycinInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Requested Quantity *

    Applicant Name *

    		 

    Salutation

    Email Address *

    		 

    Phone Number *

    Department

    		 

    Organization Name *

    City

    State

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Veratramine
    Cat. No.:
    HY-N0837
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (396 KB) Français - FR (396 KB) Deutsch - DE (396 KB) Norwegian - NO (396 KB) Español - ES (396 KB) Swedish - SV (396 KB) Italian - IT (396 KB) Korean - KR (396 KB) Portuguese - PT (396 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.